on this page
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with momelotinib and ruxolitinib under the National Health Act 1953, section 85 for patients with myelofibrosis and classified as either:
- high risk or intermediate-2 risk
- intermediate-1 risk.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing ruxolitinib.
Authority applications
Applying for initial treatment
Applications for initial authority approval to prescribe PBS-subsidised momelotinib or ruxolitinib to treat myelofibrosis can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Authority line.
Applying for continuing treatment
Continuing PBS-subsidised treatment with momelotinib or ruxolitinib is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.
More information
Call the PBS Authority line for more information.